Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • IDSA
IDSA 2025 Update: Stronger Flu and RSV Vaccine Recommendations for Immunocompromised People — What Clinicians Need to Know
Posted inInfectious Diseases news Public Health

IDSA 2025 Update: Stronger Flu and RSV Vaccine Recommendations for Immunocompromised People — What Clinicians Need to Know

Posted by MedXY By MedXY 11/23/2025
The Infectious Diseases Society of America now recommends annual high-dose or adjuvanted influenza vaccine and a single RSV dose for most immunocompromised persons; timing around immunosuppression and household immunization are emphasized.
Read More
  • Donor Diabetes Status Does Not Compromise DMEK Outcomes: 1-Year Results from the DEKS Randomized Clinical Trial
  • Molecular Imaging and PET-Guided Dose Escalation Revolutionize Salvage Radiotherapy: Insights from EMPIRE-1 and EMPIRE-2
  • Modulating Starch Digestibility: A Practical Strategy for Optimizing Glycemic Variability in Type 2 Diabetes
  • Multimodal AI Outperforms Clinical Nomograms in Predicting Metastasis for Post-Prostatectomy Biochemical Recurrence
  • Tirzepatide and the Future of MASH Treatment: Insights from the SYNERGY-NASH Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in